Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Biogen clinical trials
The registry lists 548 studies whose lead sponsor is Biogen or one of 5 companies grouped under it. 27 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Keep track of what changes. Save the Biogen studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Biogen.
- Biogen511 studiesSame company
Something wrong?
- Apellis Pharmaceuticals, Inc.28 studies →Acquired — became part of Biogen, May 14, 2026 · source ↗
Something wrong?
- 5 studies →
- Convergence Pharmaceuticals2 studies →Acquired — became part of Biogen, Feb 12, 2015 · source ↗
Something wrong?
- 1 study →
- Reata, a wholly owned subsidiary of Biogen1 study →Acquired — became part of Biogen, Sep 26, 2023 · source ↗
Something wrong?
Focus areas
Conditions Biogen leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 548. Browse all 548 →
- A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)RecruitingNCT07221669Phase 3
- A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular InflammationRecruitingNCT07219043Phase 2
- A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years OldRecruitingNCT07722546Phase 2
- A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN)Not yet recruitingNCT07889362Phase 2
- A Study to Learn More About Friedrich's Ataxia in People Living in the Gulf Cooperation Council (GCC) Region of the WorldNot yet recruitingNCT07887828
- A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS)RecruitingNCT07855211Phase 1/2
- A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene AbeparvovecRecruitingNCT07444450Phase 3
- A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)RecruitingNCT06935357Phase 3
- A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)Enrolling by invitationNCT07444489Phase 3
- A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)Enrolling by invitationNCT05352919Phase 3
- A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With RisdiplamRecruitingNCT07444476Phase 3
- A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)RecruitingNCT06962800Phase 3
- A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting ZuranoloneRecruitingNCT07398469
- A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)RecruitingNCT06555419Phase 1
- A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental GlomerulosclerosisRecruitingNCT07213960Phase 2/3
Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen
- Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)RecruitingNCT05658497
- A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusEnrolling by invitationNCT06044337Phase 3
- A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18 to 55 Years Old as Compared to a PlaceboRecruitingNCT07662148Phase 1
- A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their BabiesRecruitingNCT06628687
- A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)RecruitingNCT04901936Phase 2
Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen
- A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular DegeneratioRecruitingNCT07215390Phase 2
Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen
- A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years OldRecruitingNCT07133828Phase 1
- A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own DoctorsRecruitingNCT06623890
- A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)RecruitingNCT07259980
- A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)Not yet recruitingNCT07483632Phase 3
- A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their BabiesRecruitingNCT05789758
- A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult ParticipantsRecruitingNCT07225517Phase 1
- A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusActive, not recruitingNCT05531565Phase 2/3
- A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene AbeparvovecActive, not recruitingNCT05575011Phase 1
- Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS SymptomsActive, not recruitingNCT04856982Phase 3
- A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their BabiesActive, not recruitingNCT05688436
- A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's AtaxiaActive, not recruitingNCT06953583Phase 3
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple SclerosisActive, not recruitingNCT03958877Phase 3
- Pediatric Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05042921
- A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their PregnancyCompletedNCT07047820
- A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's AtaxiaCompletedNCT02255435Phase 2
- A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years OldActive, not recruitingNCT06054893Phase 1
- Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft TransplantationWithdrawnNCT07020832Phase 3
Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen
- A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)Active, not recruitingNCT07223723Phase 4
- A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)CompletedNCT04729907Phase 3
- Adult Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05618379
- Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium)Active, not recruitingNCT04317794
- A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years OldCompletedNCT06064929Phase 1
Sponsor listed in the registry: HI-Bio, A Biogen Company · First submitted before HI-Bio became part of Biogen
- A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled Diranersen (BIIB080) Co-administered With Diranersen in Healthy AdultsCompletedNCT06454721Phase 1
- A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of AgeActive, not recruitingNCT05399888Phase 2
- An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMDCompletedNCT04770545Phase 3
Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen
- A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)Active, not recruitingNCT06685757Phase 3
- Pegcetacoplan Long Term Safety and Efficacy Extension StudyCompletedNCT03531255Phase 3
Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen
- A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80CompletedNCT05348785Phase 2
- A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular DegenerationActive, not recruitingNCT06161584
Sponsor listed in the registry: Apellis Pharmaceuticals, Inc. · First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen